BLT - Blis Technologies

[THEONE]

It would be great to see Barry taking up his rights.
That would be a huge vote of confidence from someone that knows.

If Otago Uni did that would be great news, as they wouldnt be usual
subscribers.
They would only subscribe if the light at the end of the tunnel
was shinnig bright.

The amounts however for the rights are quite alot eg Barry Richardson around $120,000!
So understandable if they dont subscribe for all.

I have wonder about that as well whether Otago Uni would sell,
maybe if the purchaser could sign some research and development with the Uni ?

It will be an interesting few months, i think the odds are pretty high that they will try and spike the share price before rights issue closes!

[Oman]

The interim report is due about 23rd Nov 2007 so that'll be the time for Barry to do another 'progress positives' presentation ...and lift the SP maybe?

[Chippie]

I Just got an email from Dr Spicer / Breeze Care

Have a look at the Oct 2007 media release (article in the Melbourne age). It looks like he is doing okay on the back of K12.


http://www.breezecare.com.au/index.html

[THEONE]

Very interesting DSM just invested in another Probiotics company
Hopefuly they are in the investing mood and want to buy 19% of Blis!
http://www.abnnewswire.net/press/en/44156/DSM.html

[KentBrockman]

Very interesting DSM just invested in another Probiotics company
Hopefuly they are in the investing mood and want to buy 19% of Blis!
http://www.abnnewswire.net/press/en/44156/DSM.html

Another mention of Blis:

http://www.nutraingredients.com/news...cs-paediatrics

[Bobby_Fischer]

Meeting over. Rights issue to proceed. Upbeat messages from the CEO:

BLT
08/11/2007
MEETING

REL: 1259 HRS BLIS Technologies Limited

MEETING: BLT: BLIS Technologies Ltd remains on track and optimistic

From: BLIS Technologies Ltd (NZX:BLT)

MediaPak: NationalPak; Community Newspapers North and South
Island

For Immediate Release

BLIS Technologies Ltd remains on track and optimistic

BLIS Technologies Ltd (NZX: BLT), developers and manufacturers of advanced
oral probiotics announced today that the company had presented two
resolutions to a special meeting of shareholders, which were voted on and
passed. The resolutions included 1) a proposal to conduct a renounceable
rights issue for up to 44,801,079 new ordinary shares. This issue will be
provided to holders of existing ordinary shares, on a pro-rata basis at a
rate of 2 additional shares for every 5 existing shares, at an issue price of
7.5 cents, and 2) to provide authorisation to the Board to allocate up to
19.99% of the ordinary shares to one or more strategic cornerstone
shareholders subject to the provisions of the Listing Rules. In addition to
passing these resolutions, the Company also indicated it was pleased with the
progress being made and remains on track with the commercial developments
that it announced at its Annual General Meeting on 1Aug 2007. The Company
also reaffirmed the expectation that it will achieve the financial targets,
which it had forecast through to the end of the fiscal year.

The Company remains firmly committed to its retail brand strategy in New
Zealand, while at the same time it has been quickly developing its global
branded ingredient strategy, which was described at the AGM. "We have been
seeking commercial partnerships with companies that have one of the top three
brands in their respective markets." According to CEO, Dr Barry Richardson,
"So far the strategy has been working for us. We have progressed our
commercial relationship with Nestle Nutrition throughout this year in the
infant formula market and are well advanced with at least two other leading
global brand manufacturers in very distinct and unrelated industries".

"The response from the market to date is that our commercial partners seem
particularly interested in the technology we have to offer," Richardson
stated. "There is a growing body of international evidence suggesting a link
between poor oral health and the increased risk of other diseases such as
cardiovascular disease. Since BLIS's technology platform is about the
maintenance of oral, throat and upper respiratory tract health, this is a
reason why we could expect a reasonable proportion of revenue from research
contracts in the coming year"

In response as to why it has taken BLIS Technologies Ltd time to gain
traction in the international market, Richardson said, "Of course we would
always like to move faster, but our potential partners are very large and
they typically spend several million dollars on product development and
testing prior to commercial rollout. By comparison, New Zealand has been a
relatively easy market to build a base of sales, but because of regulatory
differences in all our major markets, it is not a model that can be easily
replicated off-shore" Richardson said. "This process has constrained the
speed at which we have been able to turn BLIS Technologies Ltd around, but I
am happy to report that:
a) Through a strong commercial partnership, we anticipate the test marketing
of BLIS K12 lozenges in China before the end of the fiscal year, while
concurrently completing regulatory approval.
b) We expect to launch in the Irish market in 2008 through a
major distributor and it is anticipated that sales could later extend to
other European countries. A major advantage to us of this relationship is
that having regulatory approval for our products firstly in Germany and now
in Ireland, is that we might anticipate easier access to the broader EU
market.
c) We have spent a great deal of effort in the Japanese,
Korean and Taiwanese markets seeking appropriate business partnerships. The
company has been engaged in recent early stage discussions with a Korean
pharmaceutical company and is optimistic that if negotiations are successful,
it might anticipate early market sales in Korea. The speed of Korean market
sales is also subject to the completion of regulatory approvals.
d) With international growth we need to provide logistical
support in-market and technical assistance for our key multinational
customers. This is a major component of our potential relationship with the
Dutch ingredient supply company, DSM Nutritionals. DSM and BLIS are now
negotiating a Marketing agreement, instead of the R&D contract proposed
earlier, targeting sales in 2008. DSM is expected to initially focus on
nutrition and food-based opportunities. Further, it is anticipated that DSM
and BLIS Technologies will later undertake a research contract to expand into
other product applications.

Richardson was asked why the company was not pursuing the same retail product
strategy internationally, as the company had done in New Zealand. He replied,
"we have undertaken a detailed investigation of the US market and concluded
that while the company could scale up its production to meet demand, the
magnitude of the marketing and distribution cost was simply beyond its
resources. Being New Zealand-made didn't help us either, as our products are
considered "technical" in nature and our suppliers and retailers would have
needed immediate and ongoing support and servicing, which would be
challenging, without incurring the significant cost of setting up offices in
the US."

"The logical approach for us was to partner with a company with specialist
marketing and distribution that would facilitate access to the top brands
within the categories of interest to us." Dr Barry Richardson said "We are
working to have our products approved in the US Food and Drug Administration,
as a food ingredient, which further expands our reach and gives us access to
the global food market and not keep us restricted to operating in the dietary
supplement market."

BLIS Technologies Ltd plans on using shareholder funds from the rights issue
to expand its development capabilities, complete FDA regulatory approval as a
food ingredient in the United States, and commercialise the next generation
of new BLIS probiotics.

Contact: Dr Barry Richardson, CEO 021 664 742
End CA:00156430 For:BLT Type:MEETING Time:2007-11-08:12:59:06

[THEONE]

There is a new pdf with more info at www.blis.co.nz.

[Oman]

Vacuous media fluff.

A wee bit harsh Columbus. Barry is certainly focusing on the rosy side of BLT prospects but there are plenty of reasons for optimism too.

Rational scepticism is a good position to hold when investing in the share market but the apparent info behind the media hype looks positive to me.

This RI is an important milestone. The next step is to see how many people take up the offer and how the SP reacts.

[Cooper]

So who was it? Or is ignorance Blis?

[Cooper]

How's the cat?

Blisfull, allegedly. The canines?